Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (vol 36, pg 444.e1, 2019)

被引：16
作者：
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Vijayan, R. S. K.
Nilsson, Monique B.
Hu, Lemei
He, Junqin
Zhang, Fahao
Pisegna, Marlese
Poteete, Alissa
Sun, Huiying
Li, Shuai
Chen, Ting
Han, Han
Negrao, Marcelo Vailati
Ahnert, Jordi Rodon
Diao, Lixia
Wang, Jing
Le, Xiuning
Meric-Bernstam, Funda
Routbort, Mark
Roeck, Brent
Yang, Zane
Raymond, Victoria M.
Lanman, Richard B.
Frampton, Garrett M.
Miller, Vincent A.
Schrock, Alexa B.
Albacker, Lee A.
Wong, Kwok-kin
Cross, Jason B.
Heymach, John V.
机构：
来源：
CANCER CELL | 2020年 / 37卷 / 03期
关键词：
D O I：
10.1016/j.ccell.2020.03.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 1 条
[1]  
ROBICHAUX JP, 2019, CANCER CELL, V36
1